General presentation of Crispr Therapeutics
Let's take a look at Crispr Therapeutics and its business and revenue streams. Indeed, knowing this company and how it generates profits will help you understand the challenges and opportunities for growth.
Crispr Therapeutics AG is a Swiss biotechnology company. The company specializes in the development of gene-based transforming drugs for the treatment of serious diseases.
The group is developing products through the Crispr gene-editing platform, which enables precise directed changes to DNA.
The company has a portfolio of therapeutic programs in various fields such as hemoglobinopathy, oncology, regenerative medicine and rare diseases.
Crispr's lead treatment candidate is CTX001 which is an Ex Vivo Crispr gene therapy aimed at the treatment of patients with transfusional beta thalassaemia or sickle cell disease of the severe variety in which a patient's haematopoietic stem cells are modified to produce high levels of foetal haemoglobin in red blood cells. The company has commercial operations in London and the UK and research and development activities in the US. It currently employs 410 people.